Genetic Licensing Program Manager
Rachel has been working in the agricultural sector within Australia and globally for over 11 years, having held senior leadership roles within Monsanto and Bayer in the areas of general management, strategy, global marketing, product management and licensing.
Rachel holds a degree in business majoring in business law and marketing, a graduate diploma in public relations, a masters in communication, and an Executive MBA through Melbourne Business School, where she was awarded the Egon Zehnder Leadership Prize.
John Montgomery has 40 years’ experience in the pharmaceutical industry including the US, UK, Australia and major Asian markets including Japan. John was CEO of Alphapharm and Regional Director, Asia Pacific for Merck Generics, and then President, Mylan Asia Pacific for 11 years from 1999 to 2010.
Alphapharm was and remains, the largest pharmaceutical company in Australia as measured by prescription volume. Since then, John was General Manager of Pfizer Established Products for Australia and NZ and now CEO of Montrose Pharma Pty Ltd. Before Alphapharm, he spent 20 years with Warner Lambert in a variety of roles including Vice President, Portfolio Management North America and Regional President Australia and NZ. He was Chairman of the Generic Medicines Industry Association (GMiA) for 6 years, representing the industry to government.
AMr Buttula has had extensive experience and success in investment research, funds management and information technology and has held numerous directorships in a number of public companies. He is currently the current Chairman of biotech companies, Rhythm Biosciences (ASX) and HitIQ (ASX)
Mr Buttula’s executive experience includes co-founder and CEO and Managing Director of IWL Limited, an online financial services company that listed on the ASX in 1999. The company grew from a market capitalisation of $48 million at listing before a takeover in 2007 by Commonwealth Bank of Australia for $373 million. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited.
Following his completion of executive duties, Mr Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited and led the acquisition of HUB24 Limited (ASX: HUB). More recently, he served on the Board as a non-executive director and Head of Audit & Risk at Imugene Limited (ASX: IMU) between 2014 and 2016.
Richard has been working with natural medicines and health products for over 10 yrs. He worked in a variety of positions before coming CEO of Blackmores Ltd the largest Australian health supplements company. Today, Blackmores is an ASX 200 company with a market capitalisation of $2 billion.
He was on the board of Complementary Medicines Australia for 7yrs and president for 5yrs. Richard understands the go to market strategies, regulatory encymraonment and distrbution channels for vitamin, mineral & nutritional supplements extremely well. He holds a Masters in Natural Sciences from the University of Cambridge.